Melanoma in dogs, explained honestly and in full.

Melanoma arises from melanocytes, the pigment-making cells, and in dogs it shows up in four main places, each with a very different personality. Oral (mouth) melanoma is the most common and the most concerning: it tends to grow quickly and spread. Nail-bed (digital) melanoma, on a toe, is also often aggressive. Cutaneous melanoma on the haired skin is frequently benign and cured by removal. And ocular (eye) melanoma is its own category. So the first thing an owner should understand is that a melanoma diagnosis is not one prognosis; it depends heavily on where the tumor started.

For the aggressive oral form, how far the cancer has already spread, its stage, is the main predictor of survival, and the differences are large. In one prospective study of 67 dogs with oral melanoma, according to PubMed, median survival fell steeply with stage: about 16.5 months at stage I, 9 months at stage II, 7.5 months at stage III, and 4.5 months at stage IV (Tellado et al., Radiology and Oncology, 2020). Those numbers come from one specific treatment and are medians, not predictions for any single dog, but they show clearly why staging, through examination, lymph-node checks, and imaging, is worth doing before choosing a plan.

Surgery to remove the tumor is usually the first step, and for benign skin melanomas it is often the only step needed. Unlike many cancers, melanoma tends to be responsive to radiation, which makes radiation therapy a useful tool for local control when surgery cannot get everything or the location is difficult.

You have probably heard about a melanoma vaccine. ONCEPT is a vaccine that trains the immune system against tyrosinase, a protein melanoma cells make; it is USDA-approved for stage II to III oral melanoma. Here honesty matters: according to PubMed, the published data are mixed as to whether it actually extends survival, and its use is genuinely debated within veterinary oncology (Pellin, Veterinary Sciences, 2022). It is reasonable to ask your oncologist about it, framed as promising and still-debated rather than settled. We dig into how ONCEPT works and why it sits where it does in our explainer on personalized versus shared-antigen vaccines. The full treatment walkthrough is in our melanoma treatment guide.

Melanoma is, interestingly, the cancer where personalized neoantigen vaccines have their clearest human proof. In people, adding a personalized vaccine to immunotherapy cut the risk of melanoma recurrence or death by about 44% in a randomized trial (Weber et al., The Lancet, 2024). That is a genuinely encouraging signal, and melanoma's heavy mutation load is part of why it works well there. But that result is in humans, and we should be equally clear about our own position: no personalized cancer vaccine, including the ones we design, has published canine efficacy data in melanoma or any other dog cancer. The human precedent is a reason to pursue the work responsibly, not a claim about what is available for dogs today. Our plain-language explainer covers how the approach works.

Two practical steps protect your options. First, if surgery is planned and any personalized approach might interest you, ask that the tumor tissue be preserved properly (our short guide explains why). Second, ask your oncologist about the tumor's location and stage, and whether radiation or the ONCEPT vaccine fit your dog's specific case. If you do not yet have a veterinary oncologist, your primary veterinarian can refer you.